Nomura Sarah O, Bhatia Harpreet S, Garg Parveen K, Karger Amy B, Guan Weihua, Cao Jing, Shapiro Michael D, Tsai Michael Y
Department of Laboratory Medicine and Pathology, University of Minnesota, 420 Delaware St SE, Minneapolis, MN 55455, USA.
Division of Cardiovascular Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Am J Prev Cardiol. 2024 Dec 11;21:100903. doi: 10.1016/j.ajpc.2024.100903. eCollection 2025 Mar.
Elevated lipoprotein(a) [Lp(a)], high-sensitivity C-Reactive Protein (hs-CRP), and total homocysteine (tHcy) are associated with atherosclerotic cardiovascular disease (ASCVD) risk. This study investigated the individual and joint associations of Lp(a), hs-CRP and tHcy with coronary heart disease (CHD) and stroke.
This study was conducted in the Multi-Ethnic Study of Atherosclerosis (MESA) cohort (2000-2017) (CHD analytic = 6,676; stroke analytic = 6,674 men and women). Associations between Lp(a) (<50 vs. ≥50 mg/dL), hs-CRP (<2 vs. ≥2 mg/L) and tHcy (<12 vs. ≥12 µmol/L) and CHD and stroke incidence were evaluated individually and jointly using Cox proportional hazards regression.
Individually, elevated tHcy was associated with CHD and stroke incidence, Lp(a) with CHD only and hs-CRP with stroke only. In combined analyses, CHD risk was higher when multiple biomarkers were elevated [hs-CRP+Lp(a), hazard ratio (HR)=1.39, 95 % confidence interval (CI): 1.06, 1.82; hs-CRP+ tHcy, HR = 1.34, 95 % CI: 1.02, 1.75; Lp(a)+ tHcy HR = 1.58, 95 % CI: 1.08, 2.30; hs-CRP+Lp(a)+ tHcy HR = 2.02, 95 % CI: 1.26, 3.24]. Stroke risk was elevated when hs-CRP and either Lp(a) (HR = 1.51, 95 % CI: 1.02, 2.23) or tHcy (HR = 2.10, 95 % CI: 1.44, 3.06) was also high, when all three biomarkers were elevated (HR = 2.99, 95 % CI: 1.61, 5.58), or when hs-CRP and tHcy (HR = 1.79, 95 % CI: 1.16, 2.76) were both high.
Risk of ASCVD was highest with concomitant elevation of tHcy, hs-CRP and Lp(a). Inclusion of tHcy and consideration of biomarker combination rather than individual biomarker levels may help better identify individuals at greatest risk for ASCVD events.
脂蛋白(a)[Lp(a)]、高敏C反应蛋白(hs-CRP)和总同型半胱氨酸(tHcy)升高与动脉粥样硬化性心血管疾病(ASCVD)风险相关。本研究调查了Lp(a)、hs-CRP和tHcy与冠心病(CHD)和中风的个体及联合关联。
本研究在动脉粥样硬化多民族研究(MESA)队列(2000 - 2017年)中进行(冠心病分析 = 6676例;中风分析 = 6674例男性和女性)。使用Cox比例风险回归分别和联合评估Lp(a)(<50 vs.≥50 mg/dL)、hs-CRP(<2 vs.≥2 mg/L)和tHcy(<12 vs.≥12 µmol/L)与冠心病和中风发病率之间的关联。
单独来看,tHcy升高与冠心病和中风发病率相关,Lp(a)仅与冠心病相关,hs-CRP仅与中风相关。在联合分析中,当多种生物标志物升高时,冠心病风险更高[hs-CRP + Lp(a),风险比(HR)=1.39,95%置信区间(CI):1.06,1.82;hs-CRP + tHcy,HR = 1.34,95% CI:1.02,1.75;Lp(a)+ tHcy HR = 1.58,95% CI:1.08,2.30;hs-CRP + Lp(a)+ tHcy HR = 2.02,95% CI:1.26,3.24]。当hs-CRP与Lp(a)(HR = 1.51,95% CI:1.02,2.23)或tHcy(HR = 2.10,95% CI:1.44,3.06)同时升高时,当所有三种生物标志物都升高时(HR = 2.99,95% CI:1.61,5.58),或者当hs-CRP和tHcy(HR = 1.79,95% CI:1.16,2.76)都升高时,中风风险升高。
tHcy、hs-CRP和Lp(a)同时升高时,ASCVD风险最高。纳入tHcy并考虑生物标志物组合而非单个生物标志物水平可能有助于更好地识别ASCVD事件风险最高的个体。